NCT06592456

A Phase III Clinical Trial Assessing the Immunogenicity and Safety of Lyophilized Live-Attenuated Varicella Vaccine in Healthy Subjects Aged 13 to 55 Years

Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Adolescents and Adults Aged Between 13 to 55 Years : a Double-Blind, Randomized, Parallel-Controlled Phase III Clinical Trial in China

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,200 (actual)
• Sponsor: Southeast University, China · Academic / Other
• Sex: All
• Age: 13 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Adolescents and adults Aged 13-55 Years: A Phase III, Randomized, Double-Blind, Active-Controlled Study

Conditions

• Chickenpox Vaccines

Interventions

Type	Name	Description
BIOLOGICAL	Chickenpox Vaccines	The vaccines require reconstitution with the provided sterile water for injection nd should be shaken well before use. Each human dose (0.5 ml) contains at least 3.3 log PFU of VZV.

Timeline

• Start date: 2019-07-21
• Primary completion: 2021-10-07
• Completion: 2021-11-08
• First posted: 2024-09-19
• Last updated: 2024-09-19

Locations

1 site across 1 country: China